Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients

Seoul National University logo

Seoul National University

Status

Withdrawn

Conditions

Autoimmune Encephalopathy

Treatments

Drug: Vigabatrin 500 MG

Study type

Interventional

Funder types

Other

Identifiers

NCT03003143
1607092776

Details and patient eligibility

About

Investigation of efficacy of vigabatrin in refractory autoimmune encephalitis patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18-85
  • Possible autoimmune encephalitis
  • Patients who have been diagnosed and treated for encephalitis for more than 4 weeks
  • Patients with epilepsy (EEG finding or clinically)

Exclusion criteria

  • septic shock, fever >38.5 ℃, O2 saturation <90%, respiratory rate >25, HR >120
  • previously, mRS=3 or mRS>3
  • MMSE<20
  • Patients who have terminal disease
  • eye problem
  • pregnancy

Trial design

0 participants in 1 patient group

Vigabatrin treatment group
Experimental group
Treatment:
Drug: Vigabatrin 500 MG

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems